Targeting ASAH2 induces ferroptosis of MDSCs, reduces MDSC accumulation, increases the activation of tumor-infiltrating cytotoxic T lymphocytes (CTLs), and inhibits tumor growth. Here, ASAH2 is linked to neoplasm.